Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) has experienced a rise in its stock price by 12.92 compared to its previous closing price of 0.34. However, the company has seen a fall of -45.12% in its stock price over the last five trading days. globenewswire.com reported 2025-06-26 that CUPERTINO, Calif., June 26, 2025 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced the pricing of its previously announced public offering with existing and new healthcare focused institutional investors for the purchase and sale of 20,000,000 shares of its common stock (or common stock equivalents in lieu thereof) together with Series C warrants to purchase up to 20,000,000 shares of common stock (the “Series C Warrants”) and Series D warrants to purchase up to 20,000,000 shares of common stock (the “Series D Warrants”), at a combined offering price of $0.50 per share and accompanying warrants, for aggregate gross proceeds of approximately $10 million before deducting placement agent fees and other offering expenses.
Is It Worth Investing in Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) Right Now?
The 36-month beta value for RVPH is at -0.06. Analysts have varying views on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for RVPH is 42.91M, and currently, shorts hold a 8.02% of that float. The average trading volume for RVPH on July 01, 2025 was 1.20M shares.
RVPH’s Market Performance
RVPH stock saw a decrease of -45.12% in the past week, with a monthly decline of -57.23% and a quarterly a decrease of -62.27%. The volatility ratio for the week is 23.31%, and the volatility levels for the last 30 days are 11.90% for Reviva Pharmaceuticals Holdings Inc (RVPH).. The simple moving average for the past 20 days is -46.75% for RVPH’s stock, with a -69.47% simple moving average for the past 200 days.
Analysts’ Opinion of RVPH
Many brokerage firms have already submitted their reports for RVPH stocks, with ROTH MKM repeating the rating for RVPH by listing it as a “Buy.” The predicted price for RVPH in the upcoming period, according to ROTH MKM is $12 based on the research report published on September 20, 2023 of the previous year 2023.
The Benchmark Company, on the other hand, stated in their research note that they expect to see RVPH reach a price target of $17. The rating they have provided for RVPH stocks is “Speculative Buy” according to the report published on June 08th, 2023.
H.C. Wainwright gave a rating of “Buy” to RVPH, setting the target price at $10 in the report published on January 24th of the previous year.
RVPH Trading at -53.30% from the 50-Day Moving Average
After a stumble in the market that brought RVPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.10% of loss for the given period.
Stock Fundamentals for RVPH
The total capital return value is set at -34.16. Equity return is now at value -916.17, with -281.12 for asset returns.
Based on Reviva Pharmaceuticals Holdings Inc (RVPH), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -73.22. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -1665.07.
Currently, EBITDA for the company is -29.88 million with net debt to EBITDA at 0.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.54.
Conclusion
In conclusion, Reviva Pharmaceuticals Holdings Inc (RVPH) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
